Table 2.
Demography of study population and medications used after first time PCI
| Variable | Study group | P value | |||
|---|---|---|---|---|---|
| Control (N = 359) | DM alone (N = 178) | HT alone (N = 382) | DM and HT (N = 315) | ||
| Gender | <0.01 | ||||
| F | 61 (17.0%) | 44 (24.7%) | 110 (28.8%) | 110 (34.9%) | |
| M | 298 (83.0%) | 134 (75.3%) | 272 (71.2%) | 205 (65.1%) | |
| CKD | <0.01 | ||||
| No | 318 (88.6%) | 132 (74.2%) | 304 (79.6%) | 196 (62.2%) | |
| Yes | 41 (11.4%) | 46 (25.8%) | 78 (20.4%) | 119 (37.8%) | |
| Hypercholesterolemia | <0.01 | ||||
| No | 145 (40.4%) | 98 (55.1%) | 145 (38.0%) | 156 (49.5%) | |
| Yes | 214 (59.6%) | 80 (44.9%) | 237 (62.0%) | 159 (50.5%) | |
| Current smoker | <0.01 | ||||
| No | 192 (53.5%) | 132 (74.2%) | 241 (63%) | 224 (71.1%) | |
| Yes | 167 (46.5%) | 46 (25.8%) | 141 (37.0%) | 91 (28.9%) | |
| Previous MI | <0.01 | ||||
| No | 209 (58.2%) | 98 (55.1%) | 278 (72.7%) | 222 (70.5%) | |
| Yes | 150 (41.8%) | 80 (44.9%) | 104 (27.2%) | 93 (29.5%) | |
| Stroke history | 0.09 | ||||
| No | 347 (96.7%) | 164 (92.1%) | 357 (93.5%) | 293 (93.0%) | |
| Yes | 12 (3.3%) | 14 (7.9%) | 25 (6.5%) | 22 (7.0%) | |
| CABG history | 0.67 | ||||
| No | 358 (99.7%) | 176 (98.9%) | 380 (99.5%) | 313 (99.4%) | |
| Yes | 1 (0.3%) | 2 (1.1%) | 2 (0.5%) | 2 (0.6%) | |
| Asprin | 0.25 | ||||
| No | 24 (6.7%) | 21 (11.8%) | 34 (8.9%) | 26 (8.3%) | |
| Yes | 335 (93.3%) | 157 (88.2%) | 348 (91.1%) | 289 (91.8%) | |
| P2Y12 inhibitors | 0.66 | ||||
| No | 65 (18.1%) | 35 (19.7%) | 64 (16.8%) | 49 (15.6%) | |
| Yes | 294 (81.9%) | 143 (80.3%) | 318 (83.3%) | 266 (84.4%) | |
| Diuretics | 0.01 | ||||
| No | 296 (82.5%) | 131 (73.6%) | 300 (78.5%) | 229 (72.7%) | |
| Yes | 63 (17.6%) | 47 (26.4%) | 82 (21.5%) | 86 (27.3%) | |
| BB | 0.10 | ||||
| No | 213 (59.3%) | 107 (60.1%) | 213 (55.8%) | 160 (50.8%) | |
| Yes | 146 (40.7%) | 71 (39.9%) | 169 (44.2%) | 155 (49.2%) | |
| CCB | <0.01 | ||||
| No | 294 (81.9%) | 126 (70.8%) | 223 (58.4%) | 197 (62.5%) | |
| Yes | 65 (18.1%) | 52 (29.2%) | 159 (41.6%) | 118 (37.5%) | |
| ACEI | <0.01 | ||||
| No | 255 (71.0%) | 127 (71.4%) | 310 (81.2%) | 254 (80.6%) | |
| Yes | 104 (29.0%) | 51 (28.7%) | 72 (18.9%) | 61 (19.4%) | |
| ARB | <0.01 | ||||
| No | 316 (88.0%) | 159 (89.3%) | 267 (69.9%) | 211 (67.0%) | |
| Yes | 43 (12.0%) | 19 (10.7%) | 115 (30.1%) | 104 (33.0%) | |
| Statin | <0.01 | ||||
| No | 232 (64.6%) | 134 (75.3%) | 214 (56.0%) | 210 (66.7%) | |
| Yes | 127 (35.4%) | 44 (24.7%) | 168 (44.0%) | 105 (33.3%) | |
| Fibrate | 0.08 | ||||
| No | 337 (93.9%) | 170 (95.5%) | 355 (92.9%) | 283 (89.8%) | |
| Yes | 22 (6.1%) | 8 (4.5%) | 27 (7.1%) | 32 (10.2%) | |
DM alone diabetes alone, HT alone hypertension alone, DM and HT both DM and hypertension, Previous MI history of previous myocardial infarction, CABG history history of coronary artery bypass graft, CKD chronic kidney disease, P2Y12 inhibitor P2Y12 receptor inhibitor of platelet, BB beta-blockers, CCB calcium channel blocker, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker